the Republic of Moldova will add vaccination against human papillomavirus (HPV) to the routine immunization schedule

Moldova (Republic Of)
NITAGs
6 February 2017

Vaccination against human papillomavirus (HPV) will be added to the routine immunization schedule in the Republic of Moldova in November 2017. Timely vaccination against HPV prevents infection with viruses that are the leading cause of cervical and other cancers. The Ministry of Health’s decision to introduce the vaccine followed the recommendation of the country’s independent national immunization technical advisory committee (NITAG) based on its thorough review of available evidence. 

Flag_of_Moldova.svg.png

WHO/Europe support for the decision-making process has included organization of a national conference and stakeholders’ meeting on HPV disease and vaccines on 29–30 September 2016 in Chisinau, Republic of Moldova. The conference brought together public health professionals and clinicians (obstetricians/gynaecologists, paediatricians, oncologists), medical academia, Ministry of Health officials, representatives of the Medical and Pharmaceutical State University, the national immunization programme, United Nations agencies and other stakeholders. They discussed the burden of cervical cancer in the Republic of Moldova and the experience of countries globally and in the European Region in implementing the HPV vaccine, including country efforts to address vaccine safety concerns, as well as other challenges and lessons learnt.

Burden of HPV-related disease

HPV poses a serious burden on public health in the Republic of Moldova. According to WHO estimates, HPV caused cervical cancer in more than 470 women and was responsible for 210 deaths in the country in 2012 alone. Cervical cancer is the third most prevalent of all cancers among women. The Republic of Moldova is among the top 5 countries in the WHO European Region with the highest cervical cancer mortality rates. The introduction of HPV vaccine along with implementation of other preventive interventions will help significantly reduce morbidity and mortality owing to cervical cancer and other HPV-related conditions.
By 2016, 28 countries of the WHO European Region and 67 countries globally introduced HPV vaccine into routine immunization programmes; and after 10 years and more than 200 million doses used, there is strong evidence to support that HPV vaccine is effective and safe. The successful introduction of HPV vaccine requires implementation of intensified public awareness activities and active involvement of health workers.

Related News & Events

  • 25 -26
    October
    United States of America
    NITAGs

    MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

    1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium
  • Costa Rica
    NITAGs

    Costa Rica introduces two new vaccines into the national immunization program

    16.10.2017

    October 2017 marks the introduction of the rotavirus and human papillomavirus (HPV) vaccines in Costa Rica’s immunization program. This decision results from the recommendations of the country National Immunization Technical Advisory Group (NITAG). Since 2001, Costa Rica’s NITAG, which is called Comisión Nacional de Vacunación y Epidemiología (National Commission on Vaccination and Epidemiology), is in charge of establishing and periodically updating the national immunization schedule as well as formulating overall policies and strategies for immunization. In order to issue the recommendations, the NITAG conducted cost-effectiveness studies that were then approved by its members.

    Read more
  • Canada
    NITAGs

    NACI mandate expands to support local decision-making on vaccine programs

    28.07.2017

    In June 2016 the Public Health Agency of Canada (PHAC) announced that the mandate of Canada’s NITAG, the National Advisory Committee on Immunization (NACI) will be expanded. In addition to the assessment of vaccine characteristics (safety, efficacy, effectiveness, and immunogenicity), NACI will also be assessing additional programmatic elements including economic evaluations, feasibility of implementation, acceptability, ethics and equity. 

    Read more